RT Journal Article
T1 Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer
A1 Bru Espino, Antonio Leonardo
A1 Bosch, R.
A1 Céspedes, M. V.
A1 Carmona Güedes, S.
A1 Pascual, E.
A1 Brú, I.
A1 Souto, J. C.
AB Although the protumoral functions of polymorphonuclear neutrophils are well known, some now-forgotten studies report antitumoral roles for these cells. The present work examines the antitumoral effect of maintained neutrophilia induced via the injection of recombinant human granulocyte colony stimulating factor (rhG-CSF, 100 μg/kg/day) in a Panc-1 subcutaneous xenograft murine model of pancreatic cancer. This treatment was compared with gemcitabine administration (120 mg/kg every two days) and a saline control (n = 6–7 mice per group). Compared to the controls, both the rhG-CSF- and gemcitabine-treated mice showed significantly suppressed tumor growth by day 4 (p < 0.001 and p = 0.013 respectively). From a mean starting volume of 106.9 ± 3.1 mm3 for all treatment groups, the final mean tumor volumes reached were 282.0 ± 30.7 mm3 for the rhG-CSF-treated mice, 202.6 ± 18.1 mm3 for the gemcitabine-treated mice and 519.4 ± 62.9 mm3 for the control mice (p < 0.004 and p < 0.01, respectively, vs. control). The rhG-CSF-treated tumors showed higher percentage necrosis than those treated with gemcitabine (37.4 ± 4.6 vs. 7.5 ± 3.0; p < 0.001). This is the first report of a clear anti-tumoral effect of rhG-CSF when used in monotherapy against pancreatic cancer. Since rhG-CSF administration is known to be associated with very few adverse events, it may offer an attractive alternative in the clinical treatment of pancreatic cancer.
PB Springer Nature
SN 2045-2322
YR 2019
FD 2019-02-27
LK https://hdl.handle.net/20.500.14352/13144
UL https://hdl.handle.net/20.500.14352/13144
LA eng
NO Bru Espino, A. L., Bosch, R., Céspedes, M. V. et al. «Antitumoral Effect of Maintained Neutrophilia Induced by rhG-CSF in a Murine Model of Pancreatic Cancer». Scientific Reports, vol. 9, n.o 1, febrero de 2019, p. 2879. DOI.org (Crossref), https://doi.org/10.1038/s41598-019-39805-y.
DS Docta Complutense
RD 3 abr 2025